The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Morgan Stanley initiates coverage of Aggreko at 'underweight'

Wed, 02nd Sep 2020 12:15

(Sharecast News) - Aggreko was under the cosh on Wednesday as Morgan Stanley initiated coverage of the stock at 'underweight' with a 400p price target.
The bank said temporary power provider Aggreko has few catalysts for a re-rating beyond a positive oil price surprise and looks more likely to face further valuation pressure rather than a re-rating.

"The economics for temporary power are not broken and a de-risked receivables book is reassuring," MS said.

It noted that with 25% of the utilities division debtors written down to zero, a material overhang has been removed. However, many legacy Aggreko emerging market customers are seeing increased indebtedness and forecast to see muted GDP recoveries, MS said.

"Using MS economists' forecasts, Aggreko's weighted geographic outlook points to a post-Covid 'GDP-minus' recovery."

Morgan Stanley also said that oil weakness, possible further impairments and a lengthy 'green' transition need to be navigated.

"With the slowest profit recovery in business services, we initiate at underweight."

At 1245 BST, the shares were down 4.9% at 427.33p.

Related Shares

More News
9 Dec 2022 10:27

Aggreko to buy Crestchic in £122m deal

(Sharecast News) - Temporary power supplier Aggreko said on Friday that it has agreed to buy specialist equipment provider Crestchic in a £122m d...

6 Aug 2021 18:20

IN BRIEF: Edinburgh court sanctions Albion's takeover of Aggreko

IN BRIEF: Edinburgh court sanctions Albion's takeover of Aggreko

2 Aug 2021 10:07

Albion puts in place financing for GBP2.32 billion Aggreko acquisition

Albion puts in place financing for GBP2.32 billion Aggreko acquisition

8 Jul 2021 21:32

IN BRIEF: Aggreko takeover clears antitrust and regulatory hurdle

IN BRIEF: Aggreko takeover clears antitrust and regulatory hurdle

26 May 2021 11:15

TOP NEWS: Carlyle offers GBP958 million for asthma drug maker Vectura

TOP NEWS: Carlyle offers GBP958 million for asthma drug maker Vectura

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.